ATR and leukemia: To determine whether SRSF2 mutations alone are sufficient to sensitize leukemia cells to ATR/CHK1/WEE1 inhibition, we modeled the mutations in two complementary systems: (i) isogenic human K562 cell lines and (ii) knock-in mouse bone marrow progenitors.